🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

My passion for finding new uses for existing drugs started long before #chasingmycure While my mom was battling brain cancer, her doctors gave her a high dose of corticosteroids which pulled her out of a coma and allowed us to have 2 additional months with her before she passed

Ancient drug reduces heart attacks? In this clip from the Medscape Podcast, Dr. Eric Topol and I discuss Colchicine’s recent FDA approval to reduce the risk of heart-attack and stroke. Colchicine has been used for gout for more than 3,000 years yet its anti-inflammatory

Thank you to AJMC for featuring Every Cure, in its latest documentary about rare disease treatment gaps! A special shout out to Geri Landman MD MPH, cofounder and chair of Moonshots for Unicorns, who does amazing work and was also featured in this piece! I have

New drug development is like starting at your own 1-yard line with a 10% chance of driving down the field to score big in the end zone. Repurposing, on the other hand, is like being on the opponent's 5-yard line – so close to making a difference. It may not bring riches, but it

So good to see Naveen Pemmaraju, MD at ASH! Can’t wait for our annual #castleman meeting tonight! #castlemanwarrior #castlemanflex cdcn.org/physicians-res…

So great to be at the ASH annual meeting where we’re holding our annual CDCN workshop and our team is giving 6 presentations (below). cdcn.org/physicians-res… Let us know if you’re in #sandiego and want to meet up! Identification of Autoantibodies

Love seeing this profile on LinkedIn News about our co-founder, David Fajgenbaum, MD!

Great to see our collaborative work/discovery between Every Cure, Penn, and CDCN selected as one of the top 7 Biotech Moments of the Year of 2023! labiotech.eu/best-biotech/b…

My top 10 books for 2023 Abraham Verghese Peter Lee Mustafa Suleyman Chris van Tulleken 🏳️‍🌈 Peter Attia Katalin Kariko Fei-Fei Li Prof Peter Hotez MD PhD DSc(hon) David Fajgenbaum, MD Anupam Jena Chris Worsham

Thinking back 13 years ago when I was fighting for my life in the ICU, I thought that there was no chance that I would survive. Nothing would have changed if I hadn't gone from just fighting to survive to fighting for a solution for my disease. Through my center at the

Love seeing this so much. #chasingmycure

From block captains to corporate leaders, we are privileged to have celebrated the diverse changemakers honored at The Citizen of the Year Awards. Together, we're making a difference in the City of Brotherly Love. ow.ly/OBON50QxoAK #CitizenOfTheYear #Changemakers

Researchers at the Cytokine Storm Treatment & Laboratory (CSTL) share insights into idiopathic multicentric Castleman disease (iMCD) and its subtypes that could potentially lead to patients benefiting from more personalized, tailored treatments. onlinelibrary.wiley.com/doi/10.1111/bj…

In this study, researchers at the Center for Cytokine Storm Treatment & Laboratory (CSTL) at Penn shed light on the burden faced by patients with idiopathic multicentric Castleman disease (IMCD) at diagnosis and long-term. haematologica.org/article/view/h…

On our continued to-do list: support David Fajgenbaum, MD and Every Cure as they help alleviate suffering for the 300M people globally battling diseases with no approved treatments. Every Cure is unlocking the full potential of existing drugs to treat every disease possible.

We love #drugrepurposing for #castleman disease, but this is our favorite one…

I’m going to have an identity crisis! Should I be the LeCount Disease Collaborative Network?!

What does Nobel Prize Winner Dr. Drew Weissman think of drug repurposing? Like us, he thinks it’s a no brainer! Developing new treatments for diseases is costly, time-consuming and driven by profit. Novel drug development requires $1-2B and 10-15 years per drug, and has a 90%

The new World Health Organization (WHO) Classification of Haematolymphoid Tumours includes a section on Castleman disease for the first time ever thanks to the CDCN SAB's Amy Chadburn, David Fajgenbaum, and Megan Lim! Explore this resource on diagnosing and treating CD here: tumourclassification.iarc.who.int

As a med student, David Fajgenbaum, MD nearly died several times from Castleman’s disease, a rare condition with no known treatment. After discovering his own cure, the Penn Medicine leader is now on a quest to help find treatments for others. ow.ly/favP50TuCwz